• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
HAN Ying,BAI Jianxue,LIU Rong,CHAI Fayong,DUAN Shutao,CAO Hongyan,ZHANG Jie.Inspection and risk analysis of post-market changes(change of production site ) of drugs--Taking Shandong Provinee as an example[J].Journal Of Pharmaceutical Research,2025,44(9):932-936[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2021times   Download 746次 QR Code for this article
Scan with your phone!
药品上市后变更(生产场地变更)检查及风险分析——以山东省为例
韩莹,柏建学,刘荣,柴发永,段书涛,曹鸿雁,张杰
Font:Larger+|Default|Smaller-
(山东省食品药品审评查验中心,山东 济南 250014)
摘要:
目的 了解山东省药品上市后变更(生产场地变更)的质量管理现状,发现生产场地变更检查共性缺陷问题,探讨上市后变更现场检查存在的主要风险点,为企业更加规范地实施上市后变更提供参考。方法 归纳法律法规对药品上市后变更(生产场地变更)要求,对2024年山东省内药品企业生产场地变更的检查缺陷进行统计分析。结果 药品上市后变更(生产场地变更)检查缺陷集中在文件管理、质量控制和质量保证、确认与验证、机构与人员等方面。结论 建议企业在实施上市后变更(生产场地变更)时应对上述缺陷进行重点关注,持续改进提升,确保质量管理体系持续有效运行。
关键词:  上市后变更  符合性检查  缺陷项目  质量风险
DOI:10.13506/j.cnki.jpr.2025.09.017
基金项目:
Publication Date:September 25, 2025
Inspection and risk analysis of post-market changes(change of production site ) of drugs--Taking Shandong Provinee as an example
HAN Ying,BAI Jianxue,LIU Rong,CHAI Fayong,DUAN Shutao,CAO Hongyan,ZHANG Jie
(Shandong Center for Food and Drug Evaluation & Inspection,Jinan 250013,China)
Abstract:
Objective To understand the current situation of quality management regarding post-market changes (changes in production sites) of drugs in Shandong Province, identify the common defect issues in the inspection of production site changes, explore the main risk points existing in the on-site inspection of post-market changes, and provide references for enterprises to implement post-market changes more standardized. Methods Summarize the requirements of laws and regulations for post-market changes (changes in production sites) of drugs, and conduct a statistical analysis of the inspection defects of production site changes of drug enterprises in Shandong Province in 2024. Results The inspection defects of post-market changes (changes in production sites) of drugs mainly concentrate on aspects such as document management, quality control and quality assurance, confirmation and verification, institutions and personnel. Conclusion It is recommended that enterprises should pay special attention to the above-mentioned defects when implementing post-market changes (changes in production sites), continuously improve and enhance them to ensure the continuous and effective operation of the quality management system.
Key words:  Post-market change  Compliance inspection  Defect items  Quality risk
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.